CNS Giant With Annual Sales in the $3 Billion Range Emerges as Supernus, Indivior Merge

U.S. pharmaceutical companies Supernus Pharmaceuticals and Indivior Pharmaceuticals agreed on Aug. 3, 2026, local time, to merge in an all-stock transaction. The combined company is expected to generate $2.2 billion in revenue this year, emerging as the largest biopharma company specializing in central nervous system (CNS) disorders. The deal is significant beyond simply increasing scale, as it is expected to generate $125 million in annual cost savings and bring 11 commercialized CNS products under a single corporate umbrella.

The combined company will retain the Supernus name, and CEO Jack Khattar, who founded the company 21 years ago, will lead the integrated organization. Under the terms of the merger, Supernus shareholders will receive 1.5401 shares of Indivior common stock for each share they own, while Indivior shareholders will receive a special cash dividend totaling $1 billion at the close of the transaction. The merger is expected to be completed in the fourth quarter of this year.

■ Sublocade holds the key, commanding 76% of the opioid market

The practical centerpiece of the merger is Indivior’s opioid use disorder (OUD) treatment Sublocade. The once-monthly, long-acting injectable generated $253 million in revenue in the second quarter of 2026 alone. That was a 21% increase from the same period a year earlier, making blockbuster status—annual sales of $1 billion—likely this year.

According to analysis by Jefferies investment banking analysts, Sublocade currently holds approximately 76% of the U.S. OUD treatment market and is protected by patents through at least 2038. In the United States, approximately 80,000 people died from opioid overdoses in 2023, while only about 17% to 18% of the estimated 5.7 million to 8.9 million people with OUD receive medication treatment. The low level of access to treatment also indicates that Sublocade has substantial room to expand its market.

■ Qelbree and Zurzuvae: Supernus’ fast-growing cards

Supernus adds the ADHD treatment Qelbree and the postpartum depression treatment Zurzuvae to its portfolio. Qelbree is a nonstimulant ADHD treatment approved by the FDA in 2021 and has recorded more than 3 million prescriptions since its launch. Second-quarter 2026 revenue was $89 million.

Zurzuvae generated $63 million in collaboration revenue from its commercialization partner Biogen during the first half of this year. The number of people with ADHD in the United States is estimated at approximately 16 million adults and 7 million children and adolescents, and demand for nonstimulant treatments continues to grow. The North American CNS drug market is projected to grow at an average annual rate of 6.13%, from approximately $39.3 billion in 2025 to approximately $64.6 billion in 2032.

CEO Khattar said the company had built a portfolio expected to grow through the 2030s across four core therapeutic areas: addiction, ADHD, depression and Parkinson disease. Indivior CEO Joe Ciaffoni also said, “The two companies will be strongly positioned to execute business development opportunities at a level that neither could have imagined independently.”

■ Implications for Korean CNS companies

The emergence of the combined Supernus will also be a direct factor for Korean companies competing in the U.S. CNS market. SK Biopharm is establishing itself in the U.S. market with the epilepsy drug cenobamate, marketed in the United States as Xcopri, and is advancing as a global CNS company. The emergence of a competitor with annual sales in the $3 billion range and 11 commercialized products will raise the competitive bar in the market.

Industry observers are watching for the possibility that the combined Supernus, with substantial cash-generation capacity, will pursue aggressive external business development to expand its pipeline. For mid-sized Korean pharmaceutical companies such as Myungin Pharmaceutical, Bukwang Pharmaceutical and Hwanin Pharmaceutical, which are expanding CNS pipelines in schizophrenia, Parkinson disease and dementia, as well as biotechs with innovative drug candidates, this could create opportunities to serve as licensing-out partners. As the global pharmaceutical market accelerates its shift toward diversifying portfolios through alliances and combinations among mid-cap pharmaceutical companies rather than relying on a single blockbuster, this structural change is expected to continue for the time being.